Cargando…

Effects of CYP3A5 Genotypes on Thrombocytopenia in Liver Transplantation Patients Treated with Tacrolimus

Background: Thrombocytopenia is a complication after liver transplantation. This study’s aims were to evaluate the role of CYP3A5 genotypes on tacrolimus-induced thrombocytopenia after orthotopic liver transplantation. Methods: In this retrospective case–control study, data from 100 patients who und...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Zhe, Chen, Qi, Liu, Juan, Li, Shan, Wang, He, Tang, Rui, Zhang, Zhenyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669143/ https://www.ncbi.nlm.nih.gov/pubmed/38002088 http://dx.doi.org/10.3390/biomedicines11113088

Ejemplares similares

Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients
por: Qu, Lihui, et al.
Publicado: (2017)

CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients
por: Li, Yi, et al.
Publicado: (2015)

Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose
por: Berger, Florine A., et al.
Publicado: (2019)

Correction: Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients
por: Qu, Lihui, et al.
Publicado: (2020)

The CYP3A5 genotypes of both liver transplant recipients and donors influence the time‐dependent recovery of tacrolimus clearance during the early stage following transplantation
por: Huang, Li, et al.
Publicado: (2021)

The Clinical Impact of the C(0)/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients
por: van Gelder, Teun, et al.
Publicado: (2020)

Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation
por: Buendía, Jefferson Antonio, et al.
Publicado: (2020)

Commentary: The Clinical Impact of the C(0)/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients
por: Thölking, Gerold, et al.
Publicado: (2021)

CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Nifedipine in Chinese Renal Transplant Patients
por: Yang, Yilei, et al.
Publicado: (2021)

CYP3A5 genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation
por: Ji, Eunhee, et al.
Publicado: (2018)

Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients
por: Pinon, Michele, et al.
Publicado: (2021)

Effect of CYP3A5 on the Once-Daily Tacrolimus Conversion in Stable Liver Transplant Patients
por: Kim, Jong Man, et al.
Publicado: (2020)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation
por: Moes, D J A R, et al.
Publicado: (2014)

Personalized Tacrolimus Dose Requirement by CYP3A5 but Not ABCB1 or ACE Genotyping in Both Recipient and Donor after Pediatric Liver Transplantation
por: Chen, Yi-kuan, et al.
Publicado: (2014)

Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation
por: Åsberg, Anders, et al.
Publicado: (2013)

Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients
por: Kagaya, Hideaki, et al.
Publicado: (2018)

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment
por: Chen, Lucy, et al.
Publicado: (2018)

Evaluating the Impact of CYP3A5 Genotype on Post-Transplant Healthcare Resource Utilization in Pediatric Renal and Heart Transplant Recipients Receiving Tacrolimus
por: Pasternak, Amy L, et al.
Publicado: (2021)

A Minimal Physiologically‐Based Pharmacokinetic Model for Tacrolimus in Living‐Donor Liver Transplantation: Perspectives Related to Liver Regeneration and the cytochrome P450 3A5 (CYP3A5) Genotype
por: Itohara, Kotaro, et al.
Publicado: (2019)

Genotype-guided model significantly improves accuracy of tacrolimus initial dosing after liver transplantation
por: Shi, Baojie, et al.
Publicado: (2022)

GRWR Correlates with the Metabolism of Tacrolimus after Pediatric Living Donor Liver Transplantation According to Donor CYP3A5 Polymorphism
por: Wan, Ping, et al.
Publicado: (2022)

CYP3A5 Genotype as a Potential Pharmacodynamic Biomarker for Tacrolimus Therapy in Ulcerative Colitis in Japanese Patients
por: Yamamoto, Yuki, et al.
Publicado: (2020)

Model based development of tacrolimus dosing algorithm considering CYP3A5 genotypes and mycophenolate mofetil drug interaction in stable kidney transplant recipients
por: Kim, Jae Hyun, et al.
Publicado: (2019)

A new donors’ CYP3A5 and recipients’ CYP3A4 cluster predicting tacrolimus disposition, and new-onset hypertension in Chinese liver transplant patients
por: Liu, Yuan, et al.
Publicado: (2017)

CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients
por: Mendrinou, Effrosyni, et al.
Publicado: (2020)

Tacrolimus pharmacokinetics are influenced by CYP3A5, age, and concomitant fluconazole in pediatric kidney transplant patients
por: Alghamdi, Alaa, et al.
Publicado: (2023)

Composite CYP3A (CYP3A4 and CYP3A5) phenotypes and influences on tacrolimus dose adjusted concentration in adult heart transplant recipients
por: Hernandez, Savine, et al.
Publicado: (2023)

The impact of CYP3A4 and CYP3A5 genetic variations on tacrolimus treatment of living‐donor Egyptian kidney transplanted patients
por: Wanas, Hanaa, et al.
Publicado: (2023)

Efficacy and Outcomes of CYP3A5 Genotype-Based Tacrolimus Dosing Compared to Conventional Body Weight-based Dosing in Living Donor Kidney Transplant Recipients
por: Raj, T. Yashwanth, et al.
Publicado: (2022)

Influence of POR*28 Polymorphisms on CYP3A5*3-Associated Variations in Tacrolimus Blood Levels at an Early Stage after Liver Transplantation
por: Nakamura, Takahiro, et al.
Publicado: (2020)

Investigation of clinical interaction between omeprazole and tacrolimus in CYP3A5 non-expressors, renal transplant recipients
por: Katsakiori, Paraskevi F, et al.
Publicado: (2010)

Tacrolimus-induced Ascites after Liver Transplant
por: Hosseini, M., et al.
Publicado: (2018)

Genetic factors underlying tacrolimus intolerance after liver transplantation
por: Liu, Yuan, et al.
Publicado: (2022)

Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR Genetic Polymorphisms on Tacrolimus Metabolism in Chinese Renal Transplant Recipients
por: Li, Chuan-Jiang, et al.
Publicado: (2014)

Impact of CYP3A5, POR, and CYP2C19 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplantation
por: Suetsugu, Kimitaka, et al.
Publicado: (2019)

Drug-induced CYP induction as therapy for tacrolimus intoxication
por: Hoppe, John M., et al.
Publicado: (2022)

Capability of Utilizing CYP3A5 Polymorphisms to Predict Therapeutic Dosage of Tacrolimus at Early Stage Post-Renal Transplantation
por: Niioka, Takenori, et al.
Publicado: (2015)

Donor CYP3A5 Gene Polymorphism Alone Cannot Predict Tacrolimus Intrarenal Concentration in Renal Transplant Recipients
por: Zhang, Mengyu, et al.
Publicado: (2020)

Impact of Tacrolimus Daily Dose Limitation in Renal Transplant Recipients Expressing CYP3A5: A Retrospective Study
por: Lenain, Rémi, et al.
Publicado: (2021)

Genotype-guided tacrolimus dosing in African American kidney transplant recipients
por: Sanghavi, K., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_70br58i3p6ce8udlrgbdmq0n49